Buy CYTX Before the Street Notices – Analyst Blog
Source: http://www.zacks.com/stock/news/17893/Buy+CYTX+Before+the+Street+Notices+-+Analyst+BlogPosted on Tuesday, March 3rd, 2009 | In Stocks to Watch
This is clearly an exciting time for Cytori Therapeutics (CYTX), as the company has begun to record product sales revenues from early-adopter Celution System placements in Europe and Asia.
Additionally, sales of StemSource cell banking are also now beginning to ramp. Ultimately, the clinical data will determine the pace at which the ramp continues in the next several years.
We have been encouraged by the small clinical data seen so far using Cytori’s technology. We think the company is in store to report a solid 4th quarter, and the Street has yet to take notice of the upside that exists over the next few years.
Today’s price represents a very attractive entry point, in our view. We are maintaining our Buy rating.
Read the full analyst report on “CYTX”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Settlement in Xerox-ACS Merger - Analyst Blog - November 24th, 2009
- Citi Expects Strong Economic Growth - Analyst Blog - November 24th, 2009
- Downgrading Expedia to Neutral - Analyst Blog - November 24th, 2009
- Foot Locker Misses Expectations - Analyst Blog - November 24th, 2009
- Patni Exceeds Estimates - Analyst Blog - November 24th, 2009
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.